Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accumulated Depreciation & Amortization (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Accumulated Depreciation & Amortization over the past 3 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $6.0 million for Q4 2025, up 46.99% from a year ago — trailing twelve months through Dec 2025 was $6.0 million (up 46.99% YoY), and the annual figure for FY2025 was $6.0 million, up 46.99%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $6.0 million at Tonix Pharmaceuticals Holding, up from $5.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for TNXP hit a ceiling of $6.3 million in Q1 2024 and a floor of $2.5 million in Q1 2023.
  • Median Accumulated Depreciation & Amortization over the past 3 years was $4.5 million (2023), compared with a mean of $4.5 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 148.78% in 2024 and later fell 27.53% in 2025.
  • Tonix Pharmaceuticals Holding's Accumulated Depreciation & Amortization stood at $5.4 million in 2023, then dropped by 23.59% to $4.1 million in 2024, then skyrocketed by 46.99% to $6.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $6.0 million (Q4 2025), $5.5 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.